Canada’s agbiotech nursery gives teething lessons
16 August, 2004 by Graeme O'NeillAustralasia’s venture capital-starved biotechnology industries probably need a fairy godmother like Canada’s Foragen Technologies Management.
FDA rejects Cyberonics device, contradicts panel
13 August, 2004 by Staff WritersThe US Food and Drug Administration has refused to approve a pacemaker-like device made by Houston-based Cyberonics to treat depression rejecting the advice of its own panel of experts.
Ag genomics centre heralds toxicity discoveries
13 August, 2004 by Graeme O'NeillTwo years after it was established, the NSW Agricultural Genomics Centre is showing its mettle, announcing the discovery of several DNA markers for genes conferring tolerance to aluminium toxicity.
Xenome CEO steps down as focus moves to US
13 August, 2004 by Melissa TrudingerXenome CEO Dr Tony Evans has stepped down as the company prepares to move into a new phase of development and activity with a focus on opportunities in the US.
UK GPs to test for asthma using Pharmaxis’ Aridol
12 August, 2004 by Renate KrelleHaving recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.
Panbio gets FDA approval for second-generation West Nile test
12 August, 2004 by Melissa TrudingerPanbio (ASX:PBO) has received approval from the FDA for an improved diagnostic immunoassay for West Nile Virus (WNV). The new test, which has increased specificity and sensitivity and is easier to use, comes a year after the company received approval for the first WNV test on the market.
Biota wins access to GSK documents
11 August, 2004 by Melissa TrudingerAn affidavit filed on behalf of Biota (ASX: BTA) in the Victorian Supreme Court this week has shown that the amount of money spent by GlaxoSmithKline in promoting Biota's drug Relenza in major markets dropped by 80 per cent in the second flu season after the drug was approved.
Eureka award winner finds chink in parasites' armour
11 August, 2004 by Graeme O'NeillMolecular parasitologist Dr Sabina Belli finds relief from the stresses of a busy research career in kayaking and white-water rafting.
Advice to inventors: if you love it, let it go
11 August, 2004 by Melissa TrudingerPioneering sleep specialist Dr Murray Johns had some good advice yesterday for medical practitioners wanting to commercialise their medical devices and inventions.
Chemeq's fall from grace continues
10 August, 2004 by Graeme O'NeillChemeq’s (ASX:CMQ) prolonged bout of the winter blues have continued even as the first commercial batches of its antimicrobial polymer flow from its new production plant in WA.
Pharmaxis healthy, despite clinical trials spend
10 August, 2004 by Melissa TrudingerPharmaxis (ASX: PXS) has released its preliminary final results, posting a loss of AUD$6 million for the 2003-2004 financial year.
Anti-GM protesters disrupt Melbourne’s Biofestival
10 August, 2004 by Graeme O'NeillAnti genetic-engineering protesters smashed full vases containing genetically modified carnations during the afternoon session of the Biofestival 2004 at the Melbourne Exhibition and Convention Centre today.
Quiet ASX debut for BioPharmica
09 August, 2004 by Melissa TrudingerBioPharmica (ASX: BPH) made its debut on the ASX on Friday afternoon, closing slightly lower than its opening price of AUD$0.25 at $0.21.
Prana settles clioquinol dispute
09 August, 2004 by Graeme O'NeillMelbourne dementia drug-hunter Prana Biotechnology Ltd (ASX:PBT, NASDAQ:PRAN) has resolved a long-running patent dispute with Greek pharma PN Gerolymatos (PNG) over the composition and uses of Prana’s former lead anti-Alzheimer’s drug, clioquinol, or PBT-1.
IP experts cast doubt on Labor FTA changes
09 August, 2004 by Melissa TrudingerIP industry doubts have emerged as to whether the Australian Labor Party's proposed changes to Free Trade Agreement legislation -- to prevent drugmakers from using spurious patents to block generics -- would be valid.
